The anti-inflammatory drug tocilizumab targets the IL-6 pathway to achieve a 54% remission rate in hard-to-treat depression.

An experimental diagnostic tool in the form of a computer game was able to quickly identify patients with depression based on ...

Though they’re not everyone’s cup of tea, video games can be some of the most fun you can have on a lazy day. The inherent ...

An experimental diagnostic tool in the form of a computer game was able to quickly identify patients with depression based on ...

Psilocybin has been proposed as a rapid-acting antidepressant (onset <2 weeks) with sustained effects (>6 weeks), but evidence from randomized clinical trials remains limited, particularly in the ...

Flow Neuroscience, a small Swedish company treating depression with brain-stimulating headsets, released early data on Monday showing that its device relieved depressive symptoms in clinical trials.

Young women with depression are more likely to have lower levels of taurine in their hippocampus than healthy controls. The corresponding study was published in Biological Psychiatry. Between 2013 and ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

The treatment consists of a Bluetooth headset that patients can connect to an app on their smartphones. It could mark a ...

– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical ...

AbbVie’s ABBV neuroscience franchise delivered solid results in the first quarter of 2026, supported by robust demand across ...